About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Dr. Goldenberg reviews cetuximab (Erbitux) combined with radiation therapy for cancer of the head and neck; sunitinib (Sutent) for gastrointestinal stromal tumors (GISTs) and advanced kidney cancer; and sorafenib tosylate (Nexavar)
for advanced renal cell carcinoma.
Marvin M. Goldenberg, PhD, RPh, MS
The authors report on advances with morphine sulfate and oxymorphone for back pain, ziconotide for chronic pain, intranasal morphine and transdermal hydromorphone for postoperative pain, fentanyl tablets for cancer-related breakthrough pain, lower-dose epidural steroids for lumbar radiculopathy and spinal stenosis, and duloxetine for diabetic peripheral neuropathic pain.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Letter to the Editor
Continuing Education Credit
The authors discuss the fundamentals of epidemiology in the context of cohort studies, case-control studies, and experimental studies (clinical trials) and describe the importance of epidemiology in making formulary decisions.
David D. Dore, PharmD, PhD Candidate, E. Paul Larrat, MBA, PhD, and F. Randy Vogenberg, RPh, PhD
David Nash, MD, MBA, discusses the improvements being made in the quality of drug delivery by the Medication Quality Subcommittee at Thomas Jefferson University Hospital.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, explains how noble efforts to manage pain in hospitals can inadvertently compromise patient safety.
Matthew Grissinger, RPh, FASCP
New FDA Commissioner to Face Vital Drug Safety Concerns: Companies Slow to Complete Postmarketing Trials
Stephen Barlas emphasizes the need for drug manufacturers to complete promised postmarketing (phase 4) trials in a timely way—this is just one of many challenges facing the new FDA Commissioner.
P&T presents the latest studies and information
about FDA approvals, drug indications, industry updates, and new devices.
The authors review rituximab (Rituxan) for patients with refractory rheumatoid arthritis.
Patty Ghazvini, PharmD, Angela Singh, PharmD, Phillip Treadwell, PharmD, Marlon Honeywell, PharmD, and Natosha Canty, MD